104 related articles for article (PubMed ID: 36082694)
1. SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy.
Park YK; Jangili P; Zi S; Kang RH; Kim D; Kim JS
Chem Commun (Camb); 2022 Sep; 58(78):10941-10944. PubMed ID: 36082694
[TBL] [Abstract][Full Text] [Related]
2. A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma.
Kang RH; Jang JE; Huh E; Kang SJ; Ahn DR; Kang JS; Sailor MJ; Yeo SG; Oh MS; Kim D; Kim HY
Nanoscale Horiz; 2020 Jul; 5(8):1213-1225. PubMed ID: 32510090
[TBL] [Abstract][Full Text] [Related]
3. ROS-responsive "smart" polymeric conjugate: Synthesis, characterization and proof-of-concept study.
Oddone N; Pederzoli F; Duskey JT; De Benedictis CA; Grabrucker AM; Forni F; Angela Vandelli M; Ruozi B; Tosi G
Int J Pharm; 2019 Oct; 570():118655. PubMed ID: 31479731
[TBL] [Abstract][Full Text] [Related]
4. A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma.
Kang RH; Park J; Kim J; Chowdhury T; Oh JH; Kim J; Shin J; Kim M; Park CK; Lee S; Lee JY; Kim D
ACS Biomater Sci Eng; 2022 Oct; 8(10):4163-4174. PubMed ID: 34196517
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, Characterization, and
Oddone N; Boury F; Garcion E; Grabrucker AM; Martinez MC; Da Ros F; Janaszewska A; Forni F; Vandelli MA; Tosi G; Ruozi B; Duskey JT
Front Pharmacol; 2020; 11():574. PubMed ID: 32425795
[TBL] [Abstract][Full Text] [Related]
6. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
Du K; Xia Q; Sun J; Feng F
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
[TBL] [Abstract][Full Text] [Related]
7. Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme.
Checa-Chavarria E; Rivero-Buceta E; Sanchez Martos MA; Martinez Navarrete G; Soto-Sánchez C; Botella P; Fernández E
Mol Pharm; 2021 Apr; 18(4):1558-1572. PubMed ID: 33645231
[TBL] [Abstract][Full Text] [Related]
8. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
[TBL] [Abstract][Full Text] [Related]
10. Esterase-responsive and size-optimized prodrug nanoparticles for effective intracranial drug delivery and glioblastoma treatment.
Ye Z; Gao L; Cai J; Wang Y; Li Y; Tong S; Yan T; Sun Q; Qi Y; Xu Y; Jiang H; Zhang S; Zhao L; Zhang S; Chen Q
Nanomedicine; 2022 Aug; 44():102581. PubMed ID: 35811067
[TBL] [Abstract][Full Text] [Related]
11. ROS triggered cleavage of thioketal moiety to dissociate prodrug nanoparticles for chemotherapy.
Pan Q; Deng X; Gao W; Chang J; Pu Y; He B
Colloids Surf B Biointerfaces; 2020 Oct; 194():111223. PubMed ID: 32615519
[TBL] [Abstract][Full Text] [Related]
12. Modified peroxamide-based reactive oxygen species (ROS)-responsive doxorubicin prodrugs.
Jafari M; Sriram V; Premnauth G; Merino E; Lee JY
Bioorg Chem; 2022 Oct; 127():105990. PubMed ID: 35785552
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma.
Lee BS; Amano T; Wang HQ; Pantoja JL; Yoon CW; Hanson CJ; Amatya R; Yen A; Black KL; Yu JS
ACS Nano; 2013 Apr; 7(4):3061-77. PubMed ID: 23557138
[TBL] [Abstract][Full Text] [Related]
14. Flucytosine-based prodrug activation by cold physical plasma.
Ahmadi M; Potlitz F; Link A; von Woedtke T; Nasri Z; Wende K
Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200061. PubMed ID: 35621706
[TBL] [Abstract][Full Text] [Related]
15. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer.
Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z
J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609
[TBL] [Abstract][Full Text] [Related]
16. Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy.
Wang J; Sun X; Mao W; Sun W; Tang J; Sui M; Shen Y; Gu Z
Adv Mater; 2013 Jul; 25(27):3670-6. PubMed ID: 23740675
[TBL] [Abstract][Full Text] [Related]
17. Human Glioblastoma Visualization: Triple Receptor-Targeting Fluorescent Complex of Dye, SIWV Tetra-Peptide, and Serum Albumin Protein.
An JM; Moon H; Verwilst P; Shin J; Kim BM; Park CK; Kim JS; Yeo SG; Kim HY; Kim D
ACS Sens; 2021 Jun; 6(6):2270-2280. PubMed ID: 34100604
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel 10-substituted-7-ethyl-10-hydroxycamptothecin (SN-38) prodrugs.
Zhou M; Liu M; He X; Yu H; Wu D; Yao Y; Fan S; Zhang P; Shi W; Zhong B
Molecules; 2014 Nov; 19(12):19718-31. PubMed ID: 25438082
[TBL] [Abstract][Full Text] [Related]
19. Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer.
Wang K; Yang B; Ye H; Zhang X; Song H; Wang X; Li N; Wei L; Wang Y; Zhang H; Kan Q; He Z; Wang D; Sun J
ACS Appl Mater Interfaces; 2019 May; 11(21):18914-18922. PubMed ID: 31055911
[TBL] [Abstract][Full Text] [Related]
20. DMAPT‑D6 induces death‑receptor‑mediated apoptosis to inhibit glioblastoma cell oncogenesis via induction of DNA damage through accumulation of intracellular ROS.
Zhang YJ; Yang DL; Qin HX; He LJ; Huang JH; Tang DY; Xu ZG; Chen ZZ; Li Y
Oncol Rep; 2021 Mar; 45(3):1261-1272. PubMed ID: 33469671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
